‘Michael Jackson’s This Is It’ moonwalks to Blu-Ray, DVD and PSP
CULVER CITY, Calif. Sony Pictures Home Entertainment offers music lovers a backstage pass to witness the King of Pop plan and create what would have been his electrifying and triumphant return to the stage when “Michael Jackson’s This Is It” debuts on Blu-Ray, DVD and PSP Jan. 26.
After breaking box office records around the world, “Michael Jackson’s This Is It” promises to dazzle viewers both young and old. Directed by Kenny Ortega, the Blu-Ray and DVD release will allow fans to go beyond the theatrical experience of the film Roger Ebert called “one of the most revealing music documentaries I’ve seen” with the two documentaries “Staging The Return: Beyond The Show” and “Staging The Return: The Adventure Begins,” in which Michael Jackson is shown developing, creating and rehearsing for his sold-out “This Is It” tour. Also available are a series of illuminating featurettes and more.
Additional features exclusive to the Blu-Ray include the complete and uncut versions of “Smooth Criminal” and “Thriller,” two all-new vignettes seen briefly in the film, along with a special “Making-of Smooth Criminal” featurette. In “Smooth Criminal,” sit back and marvel as Michael Jackson seamlessly shares the screen with some of the greatest movie stars of all-time in a new black and white vignette that celebrates Michael’s love of ‘Old Hollywood.’ Then, in the all-new “Thriller” vignette, watch in awe as Michael brings one of his most popular songs to a monstrous second life in a thrilling new video featuring a whole new cast of zombies, ghosts and ghouls igniting awareness with all-new and signature Jackson dance moves.
“Michael Jackson’s This Is It”, available on Blu-Ray, DVD and PSP, at an suggested retail price of $39.95, $28.96 and $24.94, respecitvely.
Kerr Drug evolves retail pharmacy with revamped community health center concept
NEW YORK Pharmacogenomics in Aisle 1?
Not quite, but the continued evolution of Kerr’s Community Healthcare Center store concept certainly offers a glimpse into what role community pharmacy could play in the American healthcare system of the future — and it goes far beyond just MTM. Like the deal CVS Caremark announced last week with Generation Health, pharmacogenomics, the study of how genetics influence drug response, represents the new frontier of community pharmacy.
In fairness, pharmacogenomics has been a part of the specialty pharmacy business for some time; given the cost of many of these drugs, the investment in DNA testing to optimize therapy is a no-brainer. But, projects like Kerr’s pilot with UNC’s Eshelman School of Pharmacy, which will focus on patients taking Plavix, target the long-term savings generated by patients on traditional drug therapies getting the most out of those medications. These types of programs will be instrumental in demonstrating community pharmacy’s value beyond simply dispensing.
It is important to note that all of the stories about innovation in community pharmacy are not generated solely by the likes of CVS Caremark and Walgreens, though clearly they are the leaders. But the story of Kerr and its Community Healthcare Center concept are an important reminder of the innovation and leadership that also continues to come out of Chapel Hill, N.C.
Study finds hypertension best treated by doctor-pharmacist collaboration
NEW YORK If anyone still doubted the extraordinary contributions that pharmacists can bring to the nation’s costly and overloaded healthcare system, the Nov. 23 issue of the Archives of Internal Medicine should lay their doubts to rest. In a report on a new and innovative approach to treating hypertension, the publication highlighted the impact that a true working collaboration between doctors and pharmacists can have on successful patient outcomes.
The report, lead-authored by Barry Carter of the University of Iowa College of Pharmacy, focused on a study of 402 people treated for high blood pressure at six clinics. Those patients were divided into two groups. Half the patients comprised a control group and were given a traditional treatment regimen for hypertension, where a prescription is written by an attending physician and the pharmacist’s role is simply to fill the script and provide basic initial counseling.
The other group was luckier. Those patients were ushered into a 21st-century style of medical practice and wellness. Their condition was managed and monitored by teams of physicians and pharmacists who were trained to adjust dosage regimens, and even the drugs dispensed, based on the patient’s ongoing condition.
The results were dramatic. After a six-month trial, 30% of patients in the control group were able to get their blood pressure down to recommended levels. More than twice as many of the patients who participated in a doctor-pharmacist team approach — 64% if them, to be exact — achieved the same improvement.
A few forward-looking health plans and insurers, such as Kaiser Permanente and the Department of Veterans Affairs — along with some of the most progressive university-affiliated medical centers, such as the Cleveland Clinic and Duke University — already pursue some collaborative-care programs. Hopefully, the results of the hypertension study will spur more such efforts.
Amid the nation’s urgent search for health reform and solutions to the unsustainable rise in chronic healthcare costs, it’s an idea whose time is long overdue.